Eli Lilly’s Morphic acquisition brings an oral small molecule that blocks the same target as Entvyio, an injectable inflammatory bowel disease drug from Takeda Pharmaceutical. The Morphic deal follows Lilly’s 2023 acquisition of Dice Therapeutics, another company developing oral immunology medications.
The post Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal appeared first on MedCity News.
Related Articles
Heat-related illnesses are preventable; here’s how
By PHIYEN NGUYEN & KRISTINA CARVALHO As we enjoy the crisp air...
WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs
Employers are prioritizing mental wellbeing programs, but employees say they need financial...
Best hospital for Congenital Hip Dislocation Treatment
Developmental dysplasia of the hip, also known as congenital hip dislocation, is...
A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria
That is the title of my recent paper with co-authors Denise Clayton,...
Leave a comment